Phase 2 Parkinson's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with advanced or metastatic non-squamous non-small cell lung cancer (a specific type of lung cancer that has spread), confirmed by a lab test on tissue or cells
• Your tumor or a blood test has shown a specific genetic change called a KRAS G12C mutation
• You are able to provide either a previously stored tumor tissue sample or a new tissue sample taken from a tumor that has not been treated with radiation
• Any side effects from previous cancer treatments have mostly gone away (back to mild or baseline levels), with some exceptions for nerve-related or hormone-related side effects
• If you have HIV, it is well controlled with medication
• If you have hepatitis B, you have been on antiviral treatment for at least 4 weeks and the virus is undetectable in your blood
• If you have hepatitis C, the virus is undetectable in your blood

Who may not be able to join:

• You have been diagnosed with small cell lung cancer, or your tumor contains small cell elements
• You have HIV and have also had a condition called Kaposi's sarcoma or Multicentric Castleman's Disease
• You have an active inflammatory bowel condition (such as Crohn's disease or ulcerative colitis) that requires immune-suppressing medication, or you have a clear history of such a condition
• You have serious uncontrolled heart or blood vessel problems — such as severe heart failure, unstable chest pain, a recent heart attack, uncontrolled irregular heartbeat, or certain abnormal heart rhythm readings — within the past 6 months
• You have previously received any systemic (whole-body) cancer treatment for advanced or metastatic non-small cell lung cancer
• You previously received immunotherapy and had to stop it because of a serious immune-related side effect (grade 3 or higher), or had to stop due to heart inflammation or recurring lung inflammation
• You have previously received any treatment that specifically targets the KRAS gene mutation
• You have received cancer treatment within the past 4 weeks (or within 5 half-lives of the drug, whichever is shorter) and have not recovered from its side effects
• You have received high-dose radiation to the lung within the past 6 months
• You have an immune system disorder, or you are taking steroid medications at higher than a low daily dose, or other immune-suppressing drugs within the past 7 days
• You have another cancer that is still growing or has needed active treatment within the past 3 years
• You have active cancer that has spread to the brain or the lining around the brain or spinal cord
• You have an active autoimmune disease (where the body attacks itself) that has needed treatment in the past 2 years (hormone replacement therapies are generally allowed — confirm with trial site)
• You have a history of non-infectious lung inflammation (pneumonitis) or scarring lung disease that needed steroid treatment, or you currently have this condition
• You have previously had a stem cell or solid organ transplant
• You have not fully recovered from a major surgery, or you still have complications from a recent surgery

Important: Always verify eligibility with the trial site directly before applying.